Abstract:The burden of sepsis as a leading cause of global morbidity and mortality is well documented. Sepsis results in high resource utilization and increasing healthcare costs often leaving survivors with life-long disabilities. Numerous novel treatment modalities have often failed in clinical trials in part, because of the heterogeneity of the disease process. These failures have highlighted the critical role that sepsis prevention and early detection play in treatment. Early recognition and prompt initiation of treatment offers the opportunity to intervene before multiple organ system failure commences. Research in the adult patient realm has made great strides with consensus definitions and work to identify biomarkers. In other areas of adult-focused research, emerging technologies have allowed for targeted therapeutics offering "precision" (or "personalized") medicine. As with many areas of medicine, research benefiting our most vulnerable patients, namely neonates and children, has lagged that of adult populations. Unfortunately, newborns and children bear a large share of the sepsis burden especially regarding mortality. 1,2 In this issue of Pediatric Research , Dr. Wang and colleagues have published their manuscript titled "Elevated Total Bile Acid Levels as an Independent Predictor of Mortality in Pediatric Sepsis". 3 In this retrospective analysis, the authors managed to perform a case-control study with 702 septic children (538 survivors and 164 non-survivors) admitted to a single pediatric intensive care unit (PICU) over a 5-year period. Importantly, the authors included an additional 269 non-infected controls that certainly strengthens the study. The authors conclude that serum total bile acids (TBA) appear to be an effective independent biomarker for predicting mortality in children with sepsis. Using a clinical model that identified TBA elevations greater than 17.9 μmol/L was an independent predictor of sepsis mortality with an AUC > 0.842, 54.9% sensitivity, and 96% specificity. Compared to control patients and sepsis survivors, the authors observed greater fluctuations and higher TBA values during hospitalization and at the time of death in the non-survivor cohort. Importantly, we believe that this study provides value by addressing two of the aforementioned challenges of pediatric sepsis – namely defining pediatric sepsis and evaluation for possible biomarkers. Wang et al. utilize the newly developed Phoenix-4 criteria to identify their septic cohort and investigate total bile acid levels as a potential biomarker. Defining sepsis across the age spectrum has been a longstanding challenge. Without clear cut age-specific definitions, treatment of sepsis in pediatric populations has relied heavily on a balance of clinical gestalt and available adult evidence. While numerous biomarkers have been investigated in pediatric sepsis, many lack the desired sensitivity and specificity or have not been widely validated in clinical use.

The evolving value of older biomarkers in the clinical diagnosis of pediatric sepsis

Role of diagnostic tests for sepsis in children: a review

Pediatric sepsis biomarkers for prognostic and predictive enrichment

Examining bile acids in pediatric sepsis – a step in the right direction

Prognostic Markers in Pediatric Critical Care: Data From the Diverse Majority*

Advancements and Clinical Applications—A Narrative Review

Sepsis Biomarkers: Advancements and Clinical Applications-A Narrative Review.

Biomarkers of Neonatal Sepsis: Where We Are and Where We Are Going

AME Evidence Series 001-the Society for Translational Medicine: Clinical Practice Guidelines for Diagnosis and Early Identification of Sepsis in the Hospital

How to use biomarkers of infection or sepsis at the bedside: guide to clinicians

Pediatric sepsis inflammatory blood biomarkers that correlate with clinical variables and severity of illness scores

Systematic review and meta-analysis of the diagnostic value of four biomarkers in detecting neonatal sepsis in low- and middle-income countries

The Clinical Application of Biomarkers in Pediatric Sepsis

Potential biomarkers used for risk estimation of pediatric sepsis-associated organ dysfunction and immune dysregulation

Mechanisms and modulation of sepsis-induced immune dysfunction in children

Biomarkers of sepsis: time for a reappraisal

Comparison of the Diagnostic Efficacy of SAA1, HBP, CRP，PCT and Cytokine Profiles for Predicting Infection in Pediatric Febrile Patients

Biomarkers for Serious Bacterial Infections in Febrile Children

Noninfectious influencers of early-onset sepsis biomarkers

Role of CD64 and myeloperoxidase as biomarkers for early diagnosis of sepsis in pediatric intensive care unit

The Current and Future State of Pediatric Sepsis Definitions: An International Survey.